Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
Gong J, Mita AC, Wei Z, Cheng HH, Mitchell EP, Wright JJ, Ivy SP, Wang V, Gray RC, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Alva AS, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.
Gong J, et al. Among authors: harris ln.
JCO Precis Oncol. 2024 Apr;8:e2300406. doi: 10.1200/PO.23.00406.
JCO Precis Oncol. 2024.
PMID: 38603651
Clinical Trial.